Ambrx Biopharma (AMAM) News Today → POTUS in ‘25 Not Biden/Trump, But (From The Freeport Society) (Ad) Free AMAM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 5, 2024 | benzinga.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)March 7, 2024 | finanznachrichten.deAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | markets.businessinsider.comJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 6, 2024 | globenewswire.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 5, 2024 | marketbeat.comFmr LLC Sells 449,560 Shares of Ambrx Biopharma Inc. (NYSE:AMAM)Fmr LLC decreased its holdings in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 20.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,761,058 shares of the company's stock after selling 44February 25, 2024 | marketbeat.com70,000 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Bought by Monashee Investment Management LLCMonashee Investment Management LLC bought a new position in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 70,000 shares of the company's stock, valuedFebruary 23, 2024 | investorplace.com3 Stocks to Buy That Are Up 200% or More in 2024February 20, 2024 | msn.comIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?February 16, 2024 | marketbeat.comAmbrx Biopharma Inc. (NYSE:AMAM) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned aFebruary 12, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMFebruary 12, 2024 | marketbeat.com47,433 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp purchased a new position in Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,433 shares of the company's stock, valued at approximately $February 10, 2024 | businesswire.comAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMJanuary 22, 2024 | marketbeat.comTD Asset Management Inc Grows Stock Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)TD Asset Management Inc lifted its stake in Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 73.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 110,456 shares of the company's stock after purchasing an additional 46,728 shareJanuary 22, 2024 | marketbeat.comAmbrx Biopharma Inc. (NYSE:AMAM) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and four have given a bJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPJanuary 16, 2024 | marketbeat.comRobert W. Baird Reiterates "Neutral" Rating for Ambrx Biopharma (NYSE:AMAM)Robert W. Baird reissued a "neutral" rating and issued a $28.00 target price on shares of Ambrx Biopharma in a research report on Tuesday.January 11, 2024 | msn.comJMP Securities Downgrades Ambrx Biopharma (AMAM)January 10, 2024 | marketbeat.comAmbrx Biopharma (NYSE:AMAM) Rating Reiterated by JMP SecuritiesJMP Securities reissued a "market perform" rating on shares of Ambrx Biopharma in a report on Wednesday.January 10, 2024 | realmoney.thestreet.comAmbrx Biopharma just downgraded at JMP Securities, here's whyJanuary 9, 2024 | finance.yahoo.comAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&JJanuary 9, 2024 | marketbeat.comAmbrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by B. RileyB. Riley reaffirmed a "neutral" rating and set a $28.00 price objective (up previously from $26.00) on shares of Ambrx Biopharma in a research report on Tuesday.January 8, 2024 | nasdaq.comJ&J to buy cancer therapy developer Ambrx for $2 blnJanuary 8, 2024 | tmcnet.comAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersJanuary 8, 2024 | marketbeat.comJohnson & Johnson: Biotech a shot in the arm for future growth? (AMAM)Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.January 8, 2024 | markets.businessinsider.comCrude Oil Falls Sharply; Ambrx Biopharma Shares Spike HigherJanuary 8, 2024 | investorplace.comWhy Is Ambrx Biopharma (AMAM) Stock Up 100% Today?January 8, 2024 | reuters.comJohnson & Johnson to buy Ambrx Biopharma for $2 blnJanuary 8, 2024 | finance.yahoo.comAmbrx Announces Sale to Johnson & JohnsonDecember 28, 2023 | marketbeat.comAmbrx Biopharma Inc. (NYSE:AMAM) Given Consensus Rating of "Moderate Buy" by AnalystsAmbrx Biopharma Inc. (NYSE:AMAM - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommenDecember 21, 2023 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Ambrx Biopharma (NYSE:AMAM)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Ambrx Biopharma in a report on Monday.December 14, 2023 | msn.comAmbrix to Join NASDAQ Biotech IndexDecember 14, 2023 | finance.yahoo.comAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)December 10, 2023 | marketbeat.comCommodore Capital LP Has $52.26 Million Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)Commodore Capital LP lowered its position in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 33.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,175,000 shares of the company's stock afterNovember 29, 2023 | markets.businessinsider.comOptimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy RatingNovember 28, 2023 | finance.yahoo.comAmbrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerNovember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)November 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)November 14, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)November 1, 2023 | msn.comAmbrx Biopharma (AMAM) Price Target Increased by 8.17% to 25.79October 26, 2023 | finance.yahoo.comCormorant Asset Management, LP Acquires New Stake in Ambrx Biopharma IncOctober 24, 2023 | msn.comRBC Capital Maintains Ambrx Biopharma (AMAM) Outperform RecommendationOctober 24, 2023 | seekingalpha.comAmbrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO DataOctober 23, 2023 | seekingalpha.comAmbrx Biopharma: Potential With Recently Released Prostate Cancer DataOctober 23, 2023 | markets.businessinsider.comAnalyst Ratings for Ambrx BiopharmaOctober 23, 2023 | finance.yahoo.comAmbrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved TreatmentsOctober 16, 2023 | benzinga.comCancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's WhyOctober 16, 2023 | finance.yahoo.comAmbrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO CongressOctober 13, 2023 | finance.yahoo.comWe're Hopeful That Ambrx Biopharma (NASDAQ:AMAM) Will Use Its Cash WiselySeptember 26, 2023 | finance.yahoo.comAmbrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023September 25, 2023 | marketbeat.comJMP Securities Initiates Coverage on Ambrx Biopharma (NYSE:AMAM)JMP Securities began coverage on shares of Ambrx Biopharma in a research report on Monday. They set an "outperform" rating and a $15.00 price objective on the stock. Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. AMAM Media Mentions By Week AMAM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMAM News Sentiment▼0.000.54▲Average Medical News Sentiment AMAM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMAM Articles This Week▼01▲AMAM Articles Average Week Get Ambrx Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INBX News Today FUSN News Today BEAM News Today ADMA News Today NMRA News Today DNA News Today RXRX News Today TARS News Today FDMT News Today VIR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AMAM) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
